Glaukos completes patient enrollment in iDose phase 2 trial

Patient enrollment in the phase 2 clinical trial of the iDose travoprost intraocular implant for glaucoma patients has been completed, Glaukos announced in a press release.

The 150-patient, multicenter, randomized, double-masked phase 2 trial will study two forms of the iDose delivery system with different elution rates against topical timolol maleate ophthalmic solution 0.5%, the release said. The investigational new drug study will evaluate the safety and efficacy of lowering IOP in patients with open-angle glaucoma and will be unmasked after 12 weeks of follow-up.

The microinvasive iDose, a titanium implant that continuously doses therapeutic levels of travoprost from within the eye over extended periods of time, is designed as an alternative to chronic daily prescription eye drop therapy.

Glaukos expects a topline readout from the study later this year.

Patient enrollment in the phase 2 clinical trial of the iDose travoprost intraocular implant for glaucoma patients has been completed, Glaukos announced in a press release.

The 150-patient, multicenter, randomized, double-masked phase 2 trial will study two forms of the iDose delivery system with different elution rates against topical timolol maleate ophthalmic solution 0.5%, the release said. The investigational new drug study will evaluate the safety and efficacy of lowering IOP in patients with open-angle glaucoma and will be unmasked after 12 weeks of follow-up.

The microinvasive iDose, a titanium implant that continuously doses therapeutic levels of travoprost from within the eye over extended periods of time, is designed as an alternative to chronic daily prescription eye drop therapy.

Glaukos expects a topline readout from the study later this year.